English  |  正體中文  |  简体中文  |  2815035  
???header.visitor??? :  27368402    ???header.onlineuser??? :  644
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

???jsp.browse.items-by-title.jump??? [ ???jsp.browse.general.jump2chinese??? ] [ ???jsp.browse.general.jump2numbers??? ] [ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ]
???jsp.browse.items-by-title.enter???   

Showing items 607851-607875 of 2307912  (92317 Page(s) Totally)
<< < 24310 24311 24312 24313 24314 24315 24316 24317 24318 24319 > >>
View [10|25|50] records per page

Institution Date Title Author
臺北醫學大學 2014 Nitroxidative chemistry interferes with fluorescent probe chemistry: implications for nitric oxide detection using 2,3-diaminonaphthalene TM, Hu;SJ, Chiu;YM, Hsu
臺北醫學大學 2014 Nitroxidative chemistry interferes with fluorescent probe chemistry: implications for nitric oxide detection using 2,3-diaminonaphthalene Hu, TM;Chiu, SJ;Hsu, YM
臺大學術典藏 2021-08-05T02:38:55Z Nitroxide polymer gels for recyclable catalytic oxidation of primary alcohols to aldehydes Xie Y;Zhang K;Yamauchi Y;Jia Z.; Xie Y; Zhang K; Yamauchi Y; Jia Z.; KEVIN CHIA-WEN WU
臺大學術典藏 2021-08-05T02:38:55Z Nitroxide radical polymers for emerging plastic energy storage and organic electronics: Fundamentals, materials, and applications Xie Y;Zhang K;Yamauchi Y;Oyaizu K;Jia Z.; Xie Y; Zhang K; Yamauchi Y; Oyaizu K; Jia Z.; KEVIN CHIA-WEN WU
國立臺灣大學 1993 Nitroxyl Free Radical Enhancement of the Forbidden O2[3Σg-]←O2(1Δg) Radiative Transition in Chlorinated Hydrocarbon Solvents Belford, R. E.; Seely, G.; Gust, D.; Moore, T. A.; Moore, A.; Cherepy, N. J.; Ekbundit, S.; Lewis, J. E.; 林聖賢; Belford, R. E.; Seely, G.; Gust, D.; Moore, T. A.; Moore, A.; Cherepy, N. J.; Ekbundit, S.; Lewis, J. E.; Lin, Sheng-Hsien
國家衛生研究院 2017-02 Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial Kang, YK;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N;Chen, LT
臺大學術典藏 2022-08-19T00:20:37Z Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M.; Ikeda M.; Chopra A.; Numata K.; Yeo W.; Kang Y.-K.; Hou M.-M.; Kim T.-Y.; Choo S.-P.; CHIUN HSU; Yau T.
臺大學術典藏 2019 Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Cruz C.D.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M.
國家衛生研究院 2017-12 Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial Kang, YK;Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Chen, LT
臺大學術典藏 2021-01-28T01:06:21Z Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Kang Y.-K.;Boku N.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Chen L.-T.; Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T.
臺大學術典藏 2017 Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I.
臺大學術典藏 2020-04-10T12:51:02Z Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Melero I.; Dastani H.B.; Tang H.; Neely J.; El-Khoueiry A.B.;Sangro B.;Yau T.;Crocenzi T.S.;Kudo M.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Trojan J.;Welling T.H.;3Rd, Meyer T.;Kang Y.-K.;Yeo W.;Chopra A.;Anderson J.;Dela Cruz C.;Lang L.;Neely J.;Tang H.;Dastani H.B.;Melero I.; El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.
國家衛生研究院 2021-03-20 Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Nishiyama, T;Chen, LT;Kang, YK
臺大學術典藏 2022-01-05T03:36:39Z Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K.
國立成功大學 2021 Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab Boku, N.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Nishiyama, T.;Chen, L.-T.;Kang, Y.-K.
國家衛生研究院 2020-09 Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study Boku, N;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Chen, LT;Kang, YK
國家衛生研究院 2022-02 Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr Kang, YK;Chen, LT;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Oh, SY;Choda, Y;Yasui, H;Takeuchi, K;Hirashima, Y;Hagihara, S;Boku, N
國立成功大學 2022 Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr Kang, Y.-K.;Chen, L.-T.;Ryu, M.-H.;Oh, D.-Y.;Oh, S.C.;Chung, H.C.;Lee, K.-W.;Omori, T.;Shitara, K.;Sakuramoto, Sakuramoto S.;Chung, I.-J.;Yamaguchi, K.;Kato, Kato K.;Sym, Sym S.J.;Kadowaki, S.;Tsuji, K.;Chen, J.-S.;Bai, L.-Y.;Oh, S.-Y.;Choda, Y.;Yasui, H.;Takeuchi, K.;Hirashima, Y.;Hagihara, S.;Boku, N.
國家衛生研究院 2023-11 Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome Su, YY;Lin, YJ;Hsiao, CF;Ou, DL;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Lee, WC;Chou, SC;Ho, CL;Chiu, CF;Chen, LT;Shen, YS;Cheng, AL;Hsu, C
國家衛生研究院 2021-07 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma Su, Y;Lin, Y;Hsiao, C;Ou, D;Chen, S;Wu, Y;Lee, W;Lin, J;Hsu, C;Ho, M;Lu, L;Wu, T;Lai, S;Chao, Y;Chou, T;Yen, C;Chen, L;Shan, Y;Cheng, A;Hsu, C
臺大學術典藏 2020-07-21T06:46:14Z Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J.
臺大學術典藏 2020-08-12T02:50:35Z Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan Chen Y.-M.;Chih-Hsin Yang J.;Su W.-C.;Chong I.-W.;Hsia T.-C.;Lin M.-C.;Chang G.-C.;Chiu C.-H.;Chao-Chi Ho;Wu S.-Y.;Hung J.-Y.;Wang C.-C.;Yang T.-Y.;Yu C.-J.; Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J.
臺大學術典藏 2022-06-27T06:59:40Z Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU
臺大學術典藏 2022-08-10T02:37:42Z Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan Chen Y.-M.; CHIH-HSIN YANG; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J.
國立成功大學 2020 Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan Chen, Y.-M.;Chih-Hsin, Yang J.;Su, W.-C.;Chong, I.-W.;Hsia, T.-C.;Lin, M.-C.;Chang, G.-C.;Chiu, Chiu C.-H.;Ho, C.-C.;Wu, S.-Y.;Hung, J.-Y.;Wang, C.-C.;Yang, T.-Y.;Yu, C.-J.

Showing items 607851-607875 of 2307912  (92317 Page(s) Totally)
<< < 24310 24311 24312 24313 24314 24315 24316 24317 24318 24319 > >>
View [10|25|50] records per page